11/12
11:33 am
iobt
IO Biotech, Inc. (NASDAQ: IOBT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Low
Report
IO Biotech, Inc. (NASDAQ: IOBT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
11/12
07:12 am
iobt
IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights [Yahoo! Finance]
Medium
Report
IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights [Yahoo! Finance]
11/12
07:05 am
iobt
IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights
High
Report
IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights
11/11
04:05 pm
iobt
IO Biotech Announces Participation in Upcoming Investor Conferences
High
Report
IO Biotech Announces Participation in Upcoming Investor Conferences
11/7
10:00 am
iobt
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study
Low
Report
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study
11/6
02:10 pm
iobt
IO Biotech, Inc. (NASDAQ: IOBT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Low
Report
IO Biotech, Inc. (NASDAQ: IOBT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
11/3
09:25 am
iobt
Here's Why We're A Bit Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Situation [Yahoo! Finance]
Neutral
Report
Here's Why We're A Bit Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Situation [Yahoo! Finance]
10/4
09:00 am
iobt
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
High
Report
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
9/16
08:03 am
iobt
IO Biotech, Inc. (NASDAQ: IOBT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Medium
Report
IO Biotech, Inc. (NASDAQ: IOBT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
9/16
08:03 am
iobt
IO Biotech, Inc. (NASDAQ: IOBT) had its price target raised by analysts at Morgan Stanley from $4.00 to $6.00. They now have an "overweight" rating on the stock.
Medium
Report
IO Biotech, Inc. (NASDAQ: IOBT) had its price target raised by analysts at Morgan Stanley from $4.00 to $6.00. They now have an "overweight" rating on the stock.
9/14
02:37 am
iobt
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer [Yahoo! Finance]
Low
Report
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer [Yahoo! Finance]
9/14
02:30 am
iobt
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
Low
Report
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
9/3
10:12 am
iobt
IO Biotech, Inc. (NASDAQ: IOBT) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $10.00 price target on the stock.
Medium
Report
IO Biotech, Inc. (NASDAQ: IOBT) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $10.00 price target on the stock.
9/3
08:04 am
iobt
IO Biotech, Inc. (NASDAQ: IOBT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
High
Report
IO Biotech, Inc. (NASDAQ: IOBT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
9/3
08:04 am
iobt
IO Biotech, Inc. (NASDAQ: IOBT) had its price target lowered by analysts at Morgan Stanley from $7.00 to $4.00. They now have an "overweight" rating on the stock.
High
Report
IO Biotech, Inc. (NASDAQ: IOBT) had its price target lowered by analysts at Morgan Stanley from $7.00 to $4.00. They now have an "overweight" rating on the stock.
9/2
07:24 am
iobt
IO Biotech's melanoma treatment trial to continue after IDMC review [Yahoo! Finance]
High
Report
IO Biotech's melanoma treatment trial to continue after IDMC review [Yahoo! Finance]
8/30
04:05 pm
iobt
IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
High
Report
IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
8/26
04:05 pm
iobt
IO Biotech Announces Participation in Upcoming Investor Conferences
Low
Report
IO Biotech Announces Participation in Upcoming Investor Conferences